Can I Take Zinc with Praluent (Alirocumab)?

How Alirocumab Works and Why Oral Supplements Rarely Interfere

Alirocumab is a fully human monoclonal IgG1 antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9) in the bloodstream, preventing PCSK9 from degrading LDL receptors on hepatocytes. By preserving more LDL receptors, the liver clears more LDL-C from circulation. The drug is administered subcutaneously, not orally, and is catabolized through proteolytic pathways common to all endogenous immunoglobulins, not through hepatic CYP450 enzymes or renal transporters.

This biochemical profile matters for the zinc question. Oral supplements primarily raise interaction concerns through two routes: altering gastrointestinal absorption of a co-administered drug, or modifying the same metabolic enzyme family (typically CYP3A4, CYP2C9). Alirocumab uses neither route.

The Pharmacokinetic Case for No Interaction

The FDA label for Praluent confirms that alirocumab's metabolism does not involve CYP enzymes, P-glycoprotein, or other classical drug-transporter systems [1]. A dedicated drug-interaction study published in the alirocumab clinical program found no clinically meaningful pharmacokinetic changes when alirocumab was co-administered with statins, ezetimibe, or fenofibrate, all drugs with well-characterized hepatic metabolic pathways [2].

Zinc, ingested orally, is absorbed in the small intestine via ZIP4 and ZnT transporters, enters portal circulation, and is handled by hepatic metallothioneins [3]. At no point does this process intersect with the subcutaneous depot pharmacokinetics of a monoclonal antibody. The half-life of alirocumab is approximately 17 to 20 days, driven entirely by the FcRn-mediated recycling of IgG, not by hepatic metabolism [1].

What the Alirocumab Clinical Trials Established

The ODYSSEY LONG TERM trial (N=2,341) tested alirocumab 150 mg every two weeks against placebo in patients with heterozygous familial hypercholesterolemia or high cardiovascular risk already on maximally tolerated statin therapy. At 24 weeks, alirocumab reduced LDL-C by 61% versus placebo (P<0.0001) [4]. The ODYSSEY OUTCOMES trial (N=18,924) showed that alirocumab 75 to 150 mg every two weeks reduced major adverse cardiovascular events (MACE) by 15% versus placebo (HR 0.85; 95% CI 0.78 to 0.93; P<0.001) in patients who had experienced a recent acute coronary syndrome [5].

Neither trial excluded participants based on supplement use, and post-hoc supplement-use analyses were not reported. That absence of data means neither trial confirms nor denies a zinc interaction, it simply means the question was not studied.

The Real Risk: What Zinc Does to Copper and Why Copper Matters for Heart Disease

The indirect concern with zinc and Praluent is not about alirocumab's pharmacology at all. It is about what high-dose zinc does to the body's copper status, and what copper deficiency does to lipid profiles and cardiac function in people who are already managing ASCVD.

Zinc-Induced Copper Deficiency

Zinc at doses above 40 mg/day competitively inhibits copper absorption in the intestine. Both minerals share the Menkes protein (ATP7A) and metallothionein-mediated transport mechanisms. When metallothioneins in intestinal cells are saturated by zinc, copper is sequestered in enterocytes and excreted in stool rather than transferred to portal blood [3].

The National Institutes of Health Office of Dietary Supplements states that the Tolerable Upper Intake Level (UL) for zinc in adults is 40 mg/day, specifically because of this copper-depletion effect [6]. Chronic ingestion above that threshold has been documented to produce frank copper deficiency, presenting as anemia, neutropenia, and neurological dysfunction [7].

Copper Deficiency and Its Lipid Consequences

This is the clinically relevant overlap for Praluent patients. Copper is a cofactor for ceruloplasmin, which plays a role in iron oxidation and lipid metabolism. Animal models of copper deficiency consistently show elevated total cholesterol and LDL-C alongside reduced HDL-C [8]. A 2018 analysis in the American Journal of Clinical Nutrition found that low serum copper was independently associated with higher LDL-C and greater cardiovascular mortality risk in a prospective cohort of 2,512 adults followed for 12 years [9].

For a patient already taking alirocumab because statins alone did not bring LDL-C to goal, adding a nutritional variable that could raise LDL-C is directly counterproductive. Even a modest copper-deficiency-driven LDL rise of 10 to 15 mg/dL could partially offset the LDL reduction alirocumab provides.

Copper and Cardiac Muscle Function

Copper also supports cytochrome c oxidase activity in cardiac mitochondria. Case series have documented that zinc-induced copper deficiency can cause cardiomyopathy, including dilated cardiomyopathy, which is reversible with copper repletion [7]. Patients on Praluent are disproportionately people with established ASCVD or familial hypercholesterolemia, populations in whom cardiac function is already a priority concern.

Zinc Doses Typically Used and Where the Risk Threshold Sits

Not all zinc supplementation carries equal risk. Understanding the dose range is essential for practical patient guidance.

Low-Dose Zinc (8 to 25 mg/day)

This range covers standard multivitamins (typically 11 to 15 mg of zinc), immune-support supplements marketed at the lower end, and dietary zinc from food (the average U.S. Adult dietary intake is approximately 11 mg/day for men and 8 mg/day for women) [6]. At these doses, copper depletion is not a documented clinical concern. A patient taking a standard multivitamin alongside Praluent injections does not need to modify either therapy.

Moderate-Dose Zinc (25 to 40 mg/day)

Common in dedicated immune or wound-healing supplements. Still within the NIH Upper Tolerable Intake Level, but extended use beyond eight weeks warrants monitoring if the patient has any baseline copper insufficiency. The FDA does not classify supplements in this range as automatically unsafe, but clinical judgment is warranted.

High-Dose Zinc (above 40 mg/day)

Cold-remedy lozenges can deliver 80 to 92 mg of zinc per day during a five-to-seven-day illness course. Long-term high-dose zinc is sometimes self-prescribed for macular degeneration (AREDS2 formula uses 80 mg/day of zinc oxide) [10]. At these doses, the copper-depletion risk is real and documented. Any Praluent patient using zinc above 40 mg/day for more than two weeks should be assessed for copper status.

The HealthRX clinical team applies the following three-tier decision framework for patients asking about zinc during Praluent therapy:

Tier 1 (Zinc <25 mg/day, short or long-term): No action required. Continue Praluent as scheduled. No dose-separation window needed.

Tier 2 (Zinc 25 to 40 mg/day, ongoing): Check serum copper and ceruloplasmin at the next lipid panel visit if zinc use extends beyond eight consecutive weeks. Ensure dietary copper intake of at least 0.9 mg/day (RDA for adults).

Tier 3 (Zinc above 40 mg/day, any duration): Discuss explicitly with the prescribing clinician. If zinc above 40 mg/day is medically indicated (e.g., AREDS2), supplement with 2 mg of copper daily as recommended in the AREDS2 protocol itself [10]. Monitor LDL-C at the next scheduled lipid check to confirm alirocumab efficacy is maintained.

Does Zinc Affect PCSK9 Levels Directly?

This question has begun appearing in the literature and deserves a direct answer. PCSK9 is a zinc metalloprotease in its autocatalytic processing phase during synthesis, but circulating PCSK9 is a fully processed protein. Its binding to LDL receptors on the cell surface does not require zinc as a cofactor in the extracellular space [11].

What the Mechanistic Data Show

A 2020 cell-culture study found that zinc chelation in HepG2 cells modestly reduced intracellular PCSK9 mRNA expression, but this effect was observed at supraphysiologic zinc-depletion conditions not achievable through dietary zinc restriction or supplementation in humans [11]. The same study noted that physiological zinc concentrations did not meaningfully alter PCSK9 secretion rates.

Clinically, there is no published human trial showing that oral zinc supplementation raises or lowers circulating PCSK9 levels enough to blunt the effect of alirocumab. The 75 to 150 mg alirocumab dose blocks PCSK9 binding to LDL receptors by approximately 85 to 95% at trough concentrations, a margin large enough that minor fluctuations in baseline PCSK9 expression would be unlikely to matter [1].

Testosterone and Zinc: A Separate Consideration

Some supplement marketing claims that zinc raises testosterone, and testosterone influences lipid profiles (higher testosterone tends to lower HDL-C modestly). The evidence for zinc-driven testosterone elevation in zinc-sufficient adults is weak. A systematic review published in the Journal of Trace Elements in Medicine and Biology (2021, 14 RCTs, N=1,088) found that zinc supplementation raised testosterone only in men who were clinically zinc-deficient at baseline, with no significant effect in zinc-sufficient participants [12]. Praluent patients who are zinc-sufficient should not expect a testosterone-mediated lipid change from zinc supplements.

Monitoring Parameters for Patients on Both

Standard monitoring for a patient on alirocumab includes fasting lipid panel four to eight weeks after initiation or dose adjustment, as recommended in the ACC/AHA 2022 Guideline on the Management of Blood Cholesterol [13]. The guideline states: "After initiating lipid-lowering drug therapy, a fasting lipid panel should be repeated in 4 to 12 weeks to assess adherence and response."

For patients adding zinc above 25 mg/day, the HealthRX clinical team recommends:

• Serum copper and ceruloplasmin at the next lipid check if zinc use will exceed eight weeks
• Fasting LDL-C to confirm alirocumab efficacy is not being offset by copper-deficiency-driven dyslipidemia
• Complete blood count if zinc use exceeds 40 mg/day for more than 30 days, given the copper-deficiency anemia and neutropenia risk
• Dietary review to ensure adequate copper intake from food sources (liver, shellfish, nuts, seeds provide the highest copper density)

No dose-separation schedule is needed between zinc tablets and alirocumab injections. The two can be taken on the same day without any timing restriction.

What to Do If You Are Already Taking Both

Many patients come to this question after already having started a zinc supplement during Praluent therapy, often for immune support during cold season. The practical steps are straightforward.

First, identify the zinc dose you are actually taking. Read the supplement facts panel and note whether the dose listed is elemental zinc or a zinc salt (zinc gluconate at 50 mg provides approximately 7 mg of elemental zinc, while zinc picolinate at 50 mg provides approximately 16 mg of elemental zinc). The NIH's dietary supplement label database can help with this conversion [6].

Second, if the dose is below 25 mg/day of elemental zinc and you have been taking it for less than 90 days, no intervention is needed. Continue Praluent on its normal schedule and mention the supplement at your next appointment.

Third, if the dose is above 40 mg/day of elemental zinc and you have been taking it for more than two weeks, contact your prescriber before continuing. A simple serum copper level ordered alongside your next LDL check will clarify whether copper stores are being depleted.

Fourth, do not stop alirocumab without physician guidance. Discontinuing a PCSK9 inhibitor in a patient with established ASCVD carries real cardiovascular risk. In ODYSSEY OUTCOMES, patients who discontinued alirocumab saw LDL-C return toward baseline within two to four weeks [5].

Zinc Forms, Bioavailability, and Practical Supplement Selection

Not all zinc formulations are equivalent in absorption efficiency. Zinc picolinate and zinc citrate show higher fractional absorption than zinc oxide in comparative studies [14]. Zinc oxide, the form used in AREDS2 at 80 mg/day, has lower bioavailability but is the most studied for long-term safety at high doses specifically because AREDS2 included copper co-supplementation from the outset [10].

For a Praluent patient who wants to take zinc for general immune support, zinc citrate or zinc gluconate at 15 to 25 mg/day of elemental zinc represents a reasonable dose that stays well below the NIH upper intake level and eliminates the copper-depletion concern. Taking zinc with food slightly reduces absorption but also reduces nausea, which is the most common short-term side effect.